1. Clinical & Scientific Overview
Fexofenadine Hydrochloride & Bilastine (TIP-MED-000182, Reference Code [9.18]) is classified under
Respiratory, Asthma, COPD & Allergy Medicines (Ch 09) as a Non-Sedating Second-Generation P-gp Substrate Histamine H1-Receptor Inverse Agonists (Schedule H).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 09 [9.18], p. 122): Fexofenadine: Allegra (Sanofi), Fexova (Ipca), Altiva (Biocon); FDC: Allegra-M (+ Montelukast 10 mg). Bilastine: Ilaxten (Menarini), Bilagra (Cipla), Bilasure (Sun); FDC: Bilagra-M — Strengths & Dosage Forms: Fexofenadine Tablets: 120 mg, 180 mg; Paediatric Suspension: 30 mg/5 mL. Bilastine Tablets: 20 mg; Paediatric Dispersible Tab / Solution: 10 mg, 2.5 mg/mL
Fexofenadine Tablets: 120 mg, 180 mg; Paediatric Suspension: 30 mg/5 mL. Bilastine Tablets: 20 mg; Paediatric Dispersible Tab / Solution: 10 mg, 2.5 mg/mL
3. Mechanism of Action & Pharmacodynamics
Non-Sedating Second-Generation P-gp Substrate Histamine H1-Receptor Inverse Agonists (Schedule H) acting on target receptor/enzyme pathways in Respiratory, Asthma, COPD & Allergy Medicines (Ch 09): clinical efficacy is mediated via Non-Sedating Second-Generation P-gp Substrate Histamine H1-Receptor Inverse Agonists (Schedule H) for Seasonal and perennial Allergic Rhinitis (120 mg Fexofenadine / 20 mg Bilastine) and Chronic Spontaneous Urticaria (180 mg Fexofenadine / 20 mg Bilastine) — ZERO blood–brain barrier penetration, zero sedation, and zero anticholinergic effects (ideal for daytime workers, drivers, students, & pilots!).
4. Therapeutic Indications & Evidence-Supported Uses
- Seasonal and perennial Allergic Rhinitis (120 mg Fexofenadine / 20 mg Bilastine) and Chronic Spontaneous Urticaria (180 mg Fexofenadine / 20 mg Bilastine) — ZERO blood–brain barrier penetration, zero sedation, and zero anticholinergic effects (ideal for daytime workers, drivers, students, & pilots!)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Fexofenadine (Adults & >=12 yr): 120 mg PO OD (Allergic Rhinitis) or 180 mg PO OD (Chronic Urticaria); Children (6–11 yr): 30 mg BD. Bilastine (Adults & >=12 yr): 20 mg PO Once Daily (Children 6–11 yr & >=20 kg: 10 mg OD)
Administration & Meal Timing: STRICT FRUIT-JUICE & FASTING OATP RULE: Both Fexofenadine and Bilastine rely on intestinal OATP influx transporters for absorption — take Bilastine (and Fexofenadine) on an EMPTY STOMACH (1h before or 2h after food) with PLAIN WATER ONLY! NEVER take with Apple, Orange, or Grapefruit juice (fruit juices block OATP transporters and cut blood levels by 60%–70%!)! | Morning (Once Daily, 1h before breakfast with plain water)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Fexofenadine: Start at 60 mg OD in severe CKD (eGFR <30 mL/min). Bilastine: No dose adjustment needed in CKD unless taking a P-gp inhibitor. Hepatic: Neither undergoes hepatic CYP450 metabolism — NO dose adjustment needed in cirrhosis!
Renal: Fexofenadine: Start at 60 mg OD in severe CKD (eGFR <30 mL/min). Bilastine: No dose adjustment needed in CKD unless taking a P-gp inhibitor. Hepatic: Neither undergoes hepatic CYP450 metabolism — NO dose adjustment needed in cirrhosis!
Renal: Fexofenadine: Start at 60 mg OD in severe CKD (eGFR <30 mL/min). Bilastine: No dose adjustment needed in CKD unless taking a P-gp inhibitor. Hepatic: Neither undergoes hepatic CYP450 metabolism — NO dose adjustment needed in cirrhosis!
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in hypersensitivity to the active substance. Safe in cardiovascular patients (no QTc prolongation and zero M1 muscarinic blockade)
Key Clinical Precautions: Renal: Fexofenadine: Start at 60 mg OD in severe CKD (eGFR <30 mL/min). Bilastine: No dose adjustment needed in CKD unless taking a P-gp inhibitor. Hepatic: Neither undergoes hepatic CYP450 metabolism — NO dose adjustment needed in cirrhosis!
8. Adverse Effects Profile
- Mild headache (3–5%); drowsiness rate is identical to placebo (~1–2%)
- Very rare hypersensitivity/angioedema
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL ABSORPTION INTERACTIONS: (1) Fruit juices (Apple, Orange, Grapefruit) & food reduce OATP-mediated absorption by 30–70%!; (2) Aluminium & Magnesium Hydroxide Antacids coat Fexofenadine and reduce absorption by 40% (separate by >=2 hours!); (3) P-gp inhibitors (Erythromycin, Ketoconazole, Itraconazole, Verapamil, Diltiazem) double plasma levels of Fexofenadine and Bilastine
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: TWO ESSENTIAL COUNTER RULES: (1) Swallow Allegra or Bilagra/Ilaxten with PLAIN WATER ONLY at least 1 hour before breakfast (taking it with food, orange juice, or apple juice blocks its absorption by up to 70%!); (2) Space at least 2 hours apart from antacids; truly non-drowsy for daytime driving and studying
- Meal & Clock Timing Instruction: STRICT FRUIT-JUICE & FASTING OATP RULE: Both Fexofenadine and Bilastine rely on intestinal OATP influx transporters for absorption — take Bilastine (and Fexofenadine) on an EMPTY STOMACH (1h before or 2h after food) with PLAIN WATER ONLY! NEVER take with Apple, Orange, or Grapefruit juice (fruit juices block OATP transporters and cut blood levels by 60%–70%!)! (Morning (Once Daily, 1h before breakfast with plain water))
- Missed Dose Protocol: Take as soon as remembered on an empty stomach; do not double dose
- Geriatric Dispensing Pearl: First-choice antihistamines in older adults >=65 years (zero BBB entry, zero anticholinergic delirium/falls/urinary retention! — AGS Beers 2023)
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Fexofenadine Tablets: 120 mg, 180 mg; Paediatric Suspension: 30 mg/5 mL. Bilastine Tablets: 20 mg; Paediatric Dispersible Tab / Solution: 10 mg, 2.5 mg/mL
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 09 [9.18] (p. 122)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [9.9]-C87 Cetirizine Dihydrochloride — Histamine H1-Receptor Inverse Agonists (Second-Generation Non-Sed
- [9.9]-C88 Chlorpheniramine Maleate (CPM) — Histamine H1-Receptor Inverse Agonists (Second-Generation Non-Sed
- [9.11]-C89 Fluticasone Furoate — Potent Topical Glucocorticoid Receptor Agonists — ICS & Intranasa
- [9.12]-C90 Beclomethasone + Formoterol / Levosalbutamol [FDC] — Inhaled Corticosteroid (ICS) Prodrug Activated by Pulmonary Ester
